MarketPulse
P

$PVLA

3 articles found
3 positive
0 negative
0 neutral
BenzingaBenzinga··Globe Newswire

Palvella Therapeutics Raises $230M in Upsized IPO to Fund Rare Disease Pipeline

Palvella Therapeutics closed $230M public offering at $125/share on February 27, 2026, fully exercising underwriter options to fund rare skin disease programs.
PVLAclinical-stagepublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Palvella Therapeutics Secures $200M in Upsized Share Offering

Palvella Therapeutics raised $200M through upsized share offering to fund clinical development of rare disease therapies including skin disease and vascular malformation treatments.
PVLAclinical-stagepublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Palvella to Present Phase 3 QTORIN Trial Results for Lymphatic Malformations

Palvella to present Phase 3 SELVA trial results for QTORIN gel treating lymphatic malformations on February 24, 2026, with data release at 6:30 a.m. ET.
PVLAPhase 3 clinical trialFDA approval